As participações na receita são estimativas para six months ended June 28, 2026, high confidence, não números de um relatório oficial.
DARZALEX
A medicine used to treat multiple myeloma, a cancer of plasma cells.
TREMFYA
A medicine for conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
CARVYKTI
A treatment made from a patient’s modified immune cells for multiple myeloma that has returned or has not responded to earlier treatment.
VARIPULSE
A system that uses pulsed electrical energy to treat atrial fibrillation, a disorder that causes an irregular heartbeat.
Impella
A heart pump used to support blood circulation in certain patients with heart failure or during high-risk heart procedures.
ACUVUE
A brand of contact lenses sold for vision correction.
Demonstrações financeiras completas →
Johnson & Johnson develops, makes and sells prescription medicines and medical devices around the world. Its two businesses are Innovative Medicine, which sells medicines for conditions including cancer and immune disorders, and MedTech, which sells products used in heart procedures, surgery, orthopaedics and vision care.
Construído a partir dos próprios documentos de Johnson & Johnson entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
The themes Johnson & Johnson is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Por InspectStocks · 20 companies
Surgical robots, implants, heart devices, glucose monitors and other medical equipment.
A 8B 7C 3D 2
Por InspectStocks · 13 companies
The largest drugmakers, selling prescription medicines worldwide.
A 7B 3C 3
US$ 286,06+0,9%fechamento 13 de nov.
Números até 27 de setembro de 2026, do 10-Q arquivado em 21 de outubro de 2026
Makes prescription medicines and medical devices for cancer, immune disorders, surgery, heart care, joint replacement and vision.
Grade A+
A faixa sob o preço mostra a nota em cada data, calculada só com os documentos já públicos naquele momento.
Mostrando 2 de 41 trimestres do histórico de notas de Johnson & Johnson. Os outros 39 vão até novembro de 2016.